The BA.3.2 variant, commonly referred to as the Cicada variant, was first identified in South Africa in November 2024. As a descendent of the BA.3 omicron subvariant that emerged in 2022, it has since raised alarms due to its significant number of mutations. Specifically, Cicada carries approximately 70 to 75 mutations in its spike protein, which is a crucial aspect of the virus that allows it to infect human cells.

As the variant spreads, it has been detected in over 20 countries, including 25 states in the United States, where its presence is currently on the rise. Health authorities are actively monitoring the BA.3.2 variant due to its increasing prevalence and the potential implications for public health. Initial observations suggest that most cases of the Cicada variant appear mild to moderate, resembling flu-like illness, particularly among vaccinated individuals.

Common symptoms associated with the Cicada variant include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. Despite the variant’s mutations, health experts emphasize that symptoms linked to the Cicada variant remain largely consistent with previous COVID-19 strains, with no new or unusual signs reported so far.

Dr. Adolfo García-Sastre, a prominent figure in infectious disease research, stated, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.” This sentiment is echoed by many health professionals who note that most cases can be managed at home with rest and hydration. Current evidence suggests that BA.3.2 does not cause more severe illness compared to earlier variants, which is a relief for many as the world continues to navigate the pandemic.

Vaccination remains a critical tool in combating the spread of the Cicada variant. While the current COVID-19 vaccines may not be as effective against it due to the multiple mutations, they are still expected to provide strong protection against severe disease, even if breakthrough infections occur. Health experts recommend that individuals stay up to date with vaccinations and take precautions in crowded settings to mitigate the risk of transmission.

As the variant continues to spread, health authorities are urging the public to remain vigilant. Observers anticipate that with ongoing monitoring and vaccination efforts, the impact of the Cicada variant can be managed effectively. However, the situation remains fluid, and details regarding the variant’s behavior and impact continue to evolve.

In summary, while the Cicada variant presents new challenges due to its mutations and spread, the symptoms it causes are largely similar to those of earlier strains. The focus remains on vaccination and public health measures to curb its transmission and protect vulnerable populations.

The post Cicada COVID Variant Symptoms: What You Need to Know appeared first on NewsNationIndia.

As the world continues to grapple with the COVID-19 pandemic, a new variant known as the Cicada variant has emerged, drawing attention for its significant number of mutations. This variant, classified as BA.3.2 and part of the Omicron family, was first spotted in South Africa in November 2024.

By early 2025, the Cicada variant began to spread to various countries, including India, where health officials are closely monitoring its impact. The variant carries approximately 75 mutations, with over 50 of these located in the spike protein, which is critical for the virus’s ability to infect human cells.

Symptoms associated with the Cicada variant include cough, extreme fatigue, runny nose, headache, sore throat, mild fever, muscle and joint pain, loss of taste or smell, night sweats, and rash. These symptoms are similar to those of previous variants, raising questions about the variant’s severity.

Currently, there is no confirmed evidence that the Cicada variant causes more severe illness than earlier strains. However, real-world data on the severity of illness caused by this variant is still limited, leaving health experts cautious.

In the United States, the first confirmed case of the Cicada variant was reported in June 2025, with three patients confirmed by January 2026, all of whom recovered. This indicates that while the variant is spreading, it may not necessarily lead to increased hospitalizations.

Dr. Robert Hopkins Jr. has noted, “It is possible we will see Cicada become the dominant strain in the U.S., but that is by no means certain.” This statement underscores the uncertainty surrounding the variant’s potential to outpace others.

The Centers for Disease Control and Prevention (CDC) has emphasized the importance of monitoring the spread of BA.3.2, stating that it provides valuable information about the potential for this new SARS-CoV-2 lineage to evade immunity from previous infections or vaccinations.

As of now, the Cicada variant has been detected in 22 countries, prompting global health authorities to remain vigilant. The situation is fluid, and health officials in India and elsewhere are preparing for various scenarios as they assess the variant’s implications.

The emergence of the Cicada variant highlights the ongoing challenges posed by COVID-19 and the need for continued surveillance and research. As the world adapts to new variants, understanding their characteristics and effects will be crucial for public health responses.

Details remain unconfirmed.

The post Cicada COVID Variant in India: A Deep Dive into Its Emergence and Implications appeared first on NewsNationIndia.

The cicada COVID variant, known scientifically as BA.3.2, has emerged as a significant concern in the United States as it spreads across at least 25 states. This heavily mutated variant, first identified in South Africa in November 2024, has raised alarms due to its potential to evade immunity from both vaccines and prior infections.

BA.3.2 is characterized by an astonishing 70 to 75 mutations in its spike protein, which may compromise the effectiveness of current vaccines. As of February 2026, it has been detected in at least 23 countries, with a notable presence in Denmark, Germany, and the Netherlands, where it accounts for approximately 30% of cases. In the U.S., it was first detected in June 2025 in a traveler returning from the Netherlands.

Experts like Andrew Pekosz, Ph.D., have noted that the numerous mutations could cause the variant to appear different to the immune system, potentially leading to reduced vaccine efficacy. “It has a lot of mutations that may cause it to look different to your immune system,” Pekosz stated, highlighting the variant’s complexity.

Despite these mutations, the World Health Organization has classified BA.3.2 as a ‘variant under monitoring’ since December 2025. However, there is currently no evidence suggesting that it causes more severe disease or higher hospitalization rates compared to previous strains. Dr. Adolfo García-Sastre reassured the public, stating, “There’s no evidence that BA.3.2 is causing more severe disease or hospitalizations in countries where it’s more widespread.”

Symptoms associated with BA.3.2 include cough, fever, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues. The variant spreads primarily through inhaling infectious respiratory particles and prolonged face-to-face interactions.

While vaccines are expected to continue providing protection against severe disease from BA.3.2, their effectiveness against infection may be reduced. Vaccination remains crucial in limiting cases, as emphasized by Pekosz, who stated, “Vaccination is still going to help limit cases.”

As of February 2026, approximately 3.7% of sewage samples nationwide have shown the presence of BA.3.2, indicating its growing prevalence. The exact reasons for the resurgence of this variant remain unclear, and the long-term impact on public health is uncertain. Details remain unconfirmed.

The post Cicada COVID Variant BA.3.2 Raises Concerns in the U.S. appeared first on NewsNationIndia.

Covid-19 continues to significantly impact global health, economies, and societies nearly three years after the virus was first identified. As governments and health organisations strive to adapt to this evolving pandemic, understanding the latest developments surrounding Covid-19 has never been more crucial. With lingering effects and new variants emerging, public awareness is essential to navigate this delicate landscape.

Recent Developments

As of October 2023, the UK has seen a slight uptick in Covid-19 cases compared to previous months, primarily attributed to the emergence of the Omicron subvariant. According to Public Health England, the number of cases rose by 15% compared to the previous month, prompting health professionals to urge individuals to remain vigilant. Vaccination rates remain high, with over 85% of the population having received at least one dose. However, booster uptake has been slow, with only 60% of eligible individuals receiving the latest jab.

Moreover, the recent availability of a new variant-focused vaccine has encouraged health authorities to launch an enhanced vaccination campaign. This new vaccine is designed to target both the original Covid-19 virus and its Omicron strains, thereby increasing immunity against the most prevalent variants.

Public Health Measures

In response to the recent rise in cases, the government has reinstated certain public health measures, including free testing for vulnerable populations and the recommendation to wear masks in crowded indoor spaces. These measures aim to mitigate the potential impact on healthcare services as winter approaches—a season traditionally associated with higher transmissibility of respiratory viruses.

Conclusion

The situation surrounding Covid-19 remains fluid, as health authorities respond to new information and trends. The potential for new variants means that public health policies may need to adapt continuously. The majority of current data indicates that vaccination remains effective in reducing severe illness and hospitalisation. For the public, staying informed and participating in vaccination campaigns are vital steps towards managing Covid-19’s impact. The continued efforts in research, vaccination, and public health compliance could pave the way for a more normal post-pandemic life. Readers are encouraged to remain updated on local health guidelines and participate in vaccination efforts to protect themselves and their communities.

The post The Ongoing Impact of Covid-19: What You Need to Know appeared first on NewsNationIndia.